Detection of Pneumococcal Pneumonia in a Phase 3 Trial Comparing Oral Solithromycin Versus Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia in Adults | Zendy

Sopio Chochua | Zendy; Amanda Sheets | Zendy; Kara Keedy | Zendy; Brian Jamieson | Zendy; David Oldach | Zendy; Prabhavathi Fernandes | Zendy; Anita Das | Zendy; Keith P. Klugman | Zendy; Jorge E. Vidal | Zendy

Open Access

Detection of Pneumococcal Pneumonia in a Phase 3 Trial Comparing Oral Solithromycin Versus Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia in Adults

Author(s) -

Sopio Chochua,

Amanda Sheets,

Kara Keedy,

Brian Jamieson,

David Oldach,

Prabhavathi Fernandes,

Anita Das,

Keith P. Klugman,

Jorge E. Vidal

Publication year - 2015

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofv133.611

Subject(s) - medicine , pneumococcal pneumonia , moxifloxacin , pneumonia , sputum , streptococcus pneumoniae , bacterial pneumonia , microbiology and biotechnology , antibiotics , pathology , biology , tuberculosis

Cempra conducted a randomized, double-blinded Phase 3 trial which evaluated the efficacy and safety of oral solithromycin (5 days) compared to the oral fluoroquinolone, moxifloxacin (7 days), for the treatment of adult patients with CABP. As pneumococcal vaccines are becoming widely used worldwide, including PCV13 (children) and PPSV23 (adults), this phase 3 trial presented a unique opportunity to further evaluate the overall prevalence of pneumococcal types causing CABP, the correlation between the pneumococcal type isolated from the nasopharynx and those strains isolated from blood or sputum and the use of pneumococcal density in nasopharyngeal specimens for detecting pneumococcal pneumonia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research